4.7 Article

Autologous Marrow Mesenchymal Stem Cell Driving Bone Regeneration in a Rabbit Model of Femoral Head Osteonecrosis

期刊

PHARMACEUTICS
卷 14, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics14102127

关键词

osteonecrosis; femoral head; bone marrow; mesenchymal stromal; stem cells; bone regeneration; cell therapy

资金

  1. European Commission [241879, 733288]
  2. Regione Emilia Romagna: Programma di Ricerca Regione-Universita 2010-2012-Strategic Program Regenerative Medicine of Cartilage and Bone [PRUa1RI-2012-007]
  3. Fondazione Guido Berlucchi Onlus
  4. Progetto MIUR Dipartimenti Eccellenti 2017

向作者/读者索取更多资源

In this study, a rabbit model was established to mimic human osteonecrosis of the femoral head (ONFH) and evaluate the autologous MSC-based treatment. Results showed that implantation of autologous BM-MSCs could restore the damaged tissue in rabbit femurs. Furthermore, the study found that osteonecrosis did not affect the behavior of MSCs.
Osteonecrosis of the femoral head (ONFH) is a progressive degenerative disease that ultimately requires a total hip replacement. Mesenchymal stromal/stem cells (MSCs), particularly the ones isolated from bone marrow (BM), could be promising tools to restore bone tissue in ONFH. Here, we established a rabbit model to mimic the pathogenic features of human ONFH and to challenge an autologous MSC-based treatment. ON has been originally induced by the synergic combination of surgery and steroid administration. Autologous BM-MSCs were then implanted in the FH, aiming to restore the damaged tissue. Histological analyses confirmed bone formation in the BM-MSC treated rabbit femurs but not in the controls. In addition, the model also allowed investigations on BM-MSCs isolated before (ON-BM-MSCs) and after (ON+BM-MSCs) ON induction to dissect the impact of ON damage on MSC behavior in an affected microenvironment, accounting for those clinical approaches foreseeing MSCs generally isolated from affected patients. BM-MSCs, isolated before and after ON induction, revealed similar growth rates, immunophenotypic profiles, and differentiation abilities regardless of the ON. Our data support the use of ON+BM-MSCs as a promising autologous therapeutic tool to treat ON, paving the way for a more consolidated use into the clinical settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据